vs

Side-by-side financial comparison of Ouster, Inc. (OUST) and TREACE MEDICAL CONCEPTS, INC. (TMCI). Click either name above to swap in a different company.

TREACE MEDICAL CONCEPTS, INC. is the larger business by last-quarter revenue ($62.5M vs $62.2M, roughly 1.0× Ouster, Inc.). On growth, Ouster, Inc. posted the faster year-over-year revenue change (106.6% vs -9.0%). TREACE MEDICAL CONCEPTS, INC. produced more free cash flow last quarter ($-10.4M vs $-37.2M). Over the past eight quarters, Ouster, Inc.'s revenue compounded faster (54.8% CAGR vs 10.6%).

Ouster, Inc. is an American lidar technology company headquartered in San Francisco, California. It builds high-resolution, digital 3D lidar sensors for use in autonomous vehicles, industrial, robotics, drones, mapping, defense, and security systems.

Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions.

OUST vs TMCI — Head-to-Head

Bigger by revenue
TMCI
TMCI
1.0× larger
TMCI
$62.5M
$62.2M
OUST
Growing faster (revenue YoY)
OUST
OUST
+115.6% gap
OUST
106.6%
-9.0%
TMCI
More free cash flow
TMCI
TMCI
$26.8M more FCF
TMCI
$-10.4M
$-37.2M
OUST
Faster 2-yr revenue CAGR
OUST
OUST
Annualised
OUST
54.8%
10.6%
TMCI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OUST
OUST
TMCI
TMCI
Revenue
$62.2M
$62.5M
Net Profit
$-9.4M
Gross Margin
60.2%
80.6%
Operating Margin
1.5%
-9.5%
Net Margin
-15.0%
Revenue YoY
106.6%
-9.0%
Net Profit YoY
-1775.0%
EPS (diluted)
$0.10
$-0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OUST
OUST
TMCI
TMCI
Q4 25
$62.2M
$62.5M
Q3 25
$39.5M
$50.2M
Q2 25
$35.0M
$47.4M
Q1 25
$32.6M
$52.6M
Q4 24
$30.1M
$68.7M
Q3 24
$28.1M
$45.1M
Q2 24
$27.0M
$44.5M
Q1 24
$25.9M
$51.1M
Net Profit
OUST
OUST
TMCI
TMCI
Q4 25
$-9.4M
Q3 25
$-21.7M
$-16.3M
Q2 25
$-20.6M
$-17.4M
Q1 25
$-22.0M
$-15.9M
Q4 24
$-501.0K
Q3 24
$-25.6M
$-15.4M
Q2 24
$-23.9M
$-21.2M
Q1 24
$-23.8M
$-18.7M
Gross Margin
OUST
OUST
TMCI
TMCI
Q4 25
60.2%
80.6%
Q3 25
42.1%
79.1%
Q2 25
45.2%
79.7%
Q1 25
41.3%
79.7%
Q4 24
43.8%
80.7%
Q3 24
38.3%
80.1%
Q2 24
33.7%
80.2%
Q1 24
28.6%
80.2%
Operating Margin
OUST
OUST
TMCI
TMCI
Q4 25
1.5%
-9.5%
Q3 25
-61.4%
-31.2%
Q2 25
-76.5%
-35.8%
Q1 25
-73.0%
-29.6%
Q4 24
-85.1%
-0.3%
Q3 24
-98.0%
-33.6%
Q2 24
-93.6%
-48.1%
Q1 24
-99.5%
-37.1%
Net Margin
OUST
OUST
TMCI
TMCI
Q4 25
-15.0%
Q3 25
-55.0%
-32.4%
Q2 25
-58.8%
-36.7%
Q1 25
-67.5%
-30.3%
Q4 24
-0.7%
Q3 24
-91.1%
-34.1%
Q2 24
-88.4%
-47.7%
Q1 24
-91.9%
-36.5%
EPS (diluted)
OUST
OUST
TMCI
TMCI
Q4 25
$0.10
$-0.14
Q3 25
$-0.37
$-0.26
Q2 25
$-0.38
$-0.28
Q1 25
$-0.42
$-0.25
Q4 24
$-0.46
$-0.01
Q3 24
$-0.54
$-0.25
Q2 24
$-0.53
$-0.34
Q1 24
$-0.55
$-0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OUST
OUST
TMCI
TMCI
Cash + ST InvestmentsLiquidity on hand
$208.6M
$48.4M
Total DebtLower is stronger
$55.6M
Stockholders' EquityBook value
$261.7M
$87.3M
Total Assets
$349.5M
$190.6M
Debt / EquityLower = less leverage
0.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OUST
OUST
TMCI
TMCI
Q4 25
$208.6M
$48.4M
Q3 25
$244.5M
$57.4M
Q2 25
$226.5M
$69.3M
Q1 25
$168.2M
$76.1M
Q4 24
$172.0M
$75.7M
Q3 24
$151.4M
$82.8M
Q2 24
$184.2M
$95.0M
Q1 24
$187.8M
$110.0M
Total Debt
OUST
OUST
TMCI
TMCI
Q4 25
$55.6M
Q3 25
$53.5M
Q2 25
$53.5M
Q1 25
$53.4M
Q4 24
$53.3M
Q3 24
$53.2M
Q2 24
$53.2M
Q1 24
$53.1M
Stockholders' Equity
OUST
OUST
TMCI
TMCI
Q4 25
$261.7M
$87.3M
Q3 25
$247.4M
$89.2M
Q2 25
$221.0M
$97.6M
Q1 25
$167.9M
$105.3M
Q4 24
$180.9M
$112.9M
Q3 24
$171.7M
$104.9M
Q2 24
$170.6M
$112.1M
Q1 24
$167.2M
$126.4M
Total Assets
OUST
OUST
TMCI
TMCI
Q4 25
$349.5M
$190.6M
Q3 25
$353.8M
$196.6M
Q2 25
$321.8M
$206.4M
Q1 25
$268.6M
$205.8M
Q4 24
$276.1M
$217.1M
Q3 24
$255.2M
$212.9M
Q2 24
$309.9M
$226.1M
Q1 24
$317.7M
$242.7M
Debt / Equity
OUST
OUST
TMCI
TMCI
Q4 25
0.64×
Q3 25
0.60×
Q2 25
0.55×
Q1 25
0.51×
Q4 24
0.47×
Q3 24
0.51×
Q2 24
0.47×
Q1 24
0.42×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OUST
OUST
TMCI
TMCI
Operating Cash FlowLast quarter
$-15.4M
$-8.0M
Free Cash FlowOCF − Capex
$-37.2M
$-10.4M
FCF MarginFCF / Revenue
-59.8%
-16.7%
Capex IntensityCapex / Revenue
35.0%
3.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-64.8M
$-29.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OUST
OUST
TMCI
TMCI
Q4 25
$-15.4M
$-8.0M
Q3 25
$-18.3M
$-9.1M
Q2 25
$-1.3M
$-3.0M
Q1 25
$-4.9M
$4.2M
Q4 24
$-2.6M
$-4.2M
Q3 24
$-3.8M
$-11.8M
Q2 24
$-21.6M
$-13.9M
Q1 24
$-5.7M
$-7.2M
Free Cash Flow
OUST
OUST
TMCI
TMCI
Q4 25
$-37.2M
$-10.4M
Q3 25
$-20.0M
$-11.9M
Q2 25
$-2.2M
$-7.8M
Q1 25
$-5.4M
$655.0K
Q4 24
$-4.0M
$-7.3M
Q3 24
$-4.3M
$-14.7M
Q2 24
$-22.0M
$-15.6M
Q1 24
$-7.1M
$-11.1M
FCF Margin
OUST
OUST
TMCI
TMCI
Q4 25
-59.8%
-16.7%
Q3 25
-50.7%
-23.7%
Q2 25
-6.3%
-16.5%
Q1 25
-16.6%
1.2%
Q4 24
-13.3%
-10.6%
Q3 24
-15.4%
-32.6%
Q2 24
-81.5%
-35.2%
Q1 24
-27.4%
-21.8%
Capex Intensity
OUST
OUST
TMCI
TMCI
Q4 25
35.0%
3.8%
Q3 25
4.3%
5.6%
Q2 25
2.5%
10.1%
Q1 25
1.7%
6.7%
Q4 24
4.8%
4.5%
Q3 24
2.0%
6.4%
Q2 24
1.3%
3.9%
Q1 24
5.3%
7.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons